T he role of the immune system in the aging process has been actively studied since seminal work in 1969. 1 A large body of evidence demonstrating chronic, low-grade elevation of inflammatory markers with increasing age has since accumulated. 2 These markers appear to derive in part from senescent cells, which are characterized by growth arrest in response to accumulated damage. Senescent cells secrete cytokines such as interleukin (IL)-6, chemokines, and proteases and are resistant to apoptosis. Although these senescent cells are less prone to malignant transformation, they may disrupt normal tissue function, promoting central adiposity, atherosclerotic plaque, and osteoporosis. 3, 4 Moreover, age-related renal dysfunction 5 and atherosclerosis 6, 7 may contribute to high inflammatory marker levels by lowering excretion and increasing production of these markers. Thus, "chronic inflammation" of aging may indicate an ongoing process of age-related damage and repair resulting in a cumulative burden of diseaserelated damage and cellular senescence.
Although conditions such as myocardial infarction, stroke, hip fracture, and arthritis contribute to disability and inflammation, growing evidence suggests that lowgrade chronic inflammation, characterized by high plasma C-reactive protein (CRP), tumor necrosis factor alpha (TNF-a), and particularly IL-6 levels, [8] [9] [10] [11] can directly impair muscle function and are independent risk factors for disability, impaired mobility, and slow walking speed. 12, 13 Based on current knowledge about the detrimental effects of chronic inflammation, it seems logical that blocking the effects or reducing the sources of chronic low-grade inflammation would have clinical benefit. Alternatively, because inflammatory pathways are tightly regulated, manipulation could have adverse effects, such as greater risk of infection or delayed healing. Therefore, it is unclear whether the observed increases in inflammation with age are detrimental or adaptive. A randomized trial targeting inflammatory pathways directly was warranted to determine which of these alternative interpretations is correct.
The ENabling Reduction of low-Grade Inflammation in SEniors (ENRGISE) Pilot Study was a randomized clinical trial to gather preliminary data to test whether antiinflammatory interventions improve or preserve walking ability. Older persons with mobility impairment and high levels of inflammation-a population at high risk of major mobility disability-were enrolled. 8, 9, 14 The aims of the ENRGISE Pilot Study were to compare the effects of losartan, omega-3 fish oil (x-3, also known as omega-3 long chain polyunsaturated fatty acids), and losartan plus x-3 with the effects of placebo on IL-6 levels and walking speed in target sample of 300 older adults (aged ≥70) over 12 months of follow-up. Secondary aims were to evaluate recruitment yields, eligibility criteria, adherence, retention, tolerability, sample size, design, and parameters affecting cost for the main randomized clinical trial, which was focused on major mobility disability as an outcome. The study also aimed to examine intrasubject variability of IL-6, dosage and safety of the interventions, and other established and novel inflammatory markers. These aims were designed to inform the feasibility of the full ENRGISE trial to assess whether targeting inflammation reduces the risk of major mobility disability. This article provides the background, rationale, conceptual basis, discussion of treatment choices, and research design of the ENRGISE Pilot Study.
METHODS

Participants and Eligibility Criteria
Men and women aged 70 and older who self-reported difficulty walking one-quarter of a mile or climbing a flight of stairs, had a usual walking speed of less than 1 m/s on a 4-m walk, and had evidence of chronic lowgrade inflammation (IL-6 2.5-30 pg/mL) were enrolled (target N = 300). IL-6 level greater than 2.5 pg/mL was chosen because of its association with risk of mobility limitation, 15, 16 and persons with a level of 30 pg/mL or greater were excluded because they were likely to have an acute infection (e.g., urinary, respiratory) that did not coincide with chronic low-grade inflammation. To reduce the effect of within-person variability, IL-6 levels were based on the average of two measures taken 1 to 3 weeks apart, with the first measure being between 2.3 and 30 pg/ mL and the average of the two measures between 2.5 and 30 pg/mL. The lower value of 2.3 pg/mL for the first measure was designed to be more inclusive of individuals with chronic low-grade inflammation, accounting for day-today variability and interassay variability. Complete eligibility criteria are listed in Table 1 .
Participants were excluded if they reported acute infection, autoimmune disease, severe arthritis, or a neurological condition causing low walking speed. Initially, participants were also excluded for having low vitamin D levels (Serum level of 25-OH Vitamin D <20 ng/ml), as required by funding opportunity announcement (RFA-AG-15-006). This requirement was dropped one-third of the way through the recruitment period because of a lack of evidence of how low vitamin D levels would affect the association between inflammation and physical function. Those who took an angiotensin-converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), or potassium-sparing diuretic were excluded from losartan randomization. Those who had eaten more than two servings per week of fish in the past year or were taking fish oil were excluded from x-3 randomization. Recruitment targets were approximately 69% female, 20% racial minorities, and 5% Hispanic, which reflected the population distribution of these subgroups in the catchment areas. The institutional review boards at each study site approved the protocol, and all participants provided written informed consent. The trial is registered at clinicaltrials.gov (identifier NCT01072500).
Study Measures and Outcomes
A timetable of measures and assessments is listed in Table S1 . IL-6 and walking speed during the 400-m walk test were identified as coprimary outcomes of the ENRGISE Pilot Study. The 400-m usual-pace walk test was used to assess major mobility disability (MMD), 17 defined as inability to walk one-quarter of a mile. MMD was operationalized as inability to complete a 400-m walk test within 15 minutes without sitting or help of another person or walker. In cases in which the 400-m walk was not attempted, MMD was adjudicated based on objective inability to walk 4-m in less than 10 seconds, self-or proxy-reported inability to walk across a room, or medical record documentation of mobility status. 17 IL-6 was prioritized over other inflammatory factors because it is a stable inflammatory marker that is less sensitive to day-to-day and diurnal variations and is the marker most consistently associated with mobility limitations. 15, 16 IL-6 levels were determined using a sandwich immunoassay (Human IL-6 Quantikine ELISA Kit, catalog #HS600B, R & D Systems, Minneapolis, MN). Levels greater than 10 pg/mL were evaluated using a 
Inclusion and Exclusion Criteria for the ENabling Reduction of low-Grade Inflammation in SEniors Pilot Study
Inclusion criteria
Men and women aged ≥70 years Self-reported difficulty walking one-quarter of a mile or climbing a flight of stairs Walking speed 0.44-1 m/s on the 4-m walk at usual pace; a walking speed of <0.44 m/s would not be compatible with completing the 400 m walk in 15 minutes. (In the pilot phase, the feasibility of at least half of participants having a baseline walking speed of 0.44-0.80 m/s was explored.) Ability to complete the 400-m walk test within 15 minutes without sitting or receiving help from another person and without a walker; a cane is allowed Blood interleukin-6 level 2.5-30 pg/mL Willingness to be randomized to the intervention groups Exclusion criteria Failure or inability to provide informed consent Living in nursing home; persons living in assisted or independent housing were not excluded Self-reported inability to walk one block Significant cognitive impairment, defined as a known diagnosis of dementia or a Mini-Mental State Examination score <24 Inability to communicate because of severe hearing loss or speech disorder Neurological conditions causing impaired muscle function or mobility (e.g., stroke with residual paresis paralysis, neuropathy, Parkinson's disease, multiple sclerosis) Severe rheumatological or orthopedic disease (e.g., awaiting joint replacement, known active inflammatory or autoimmune disease (e.g., rheumatoid arthritis, lupus, Crohn's disease, human immunodeficiency virus) Terminal illness with life expectancy <12 months Severe pulmonary disease requiring either pills or injections Other significant comorbid disease that in the opinion of the field center primary investigator would impair ability to participate in the trial (e.g., renal failure on hemodialysis, severe psychiatric disorder (e.g., bipolar, schizophrenia), excessive alcohol use (>14 drinks per week), drug addiction, treatment for cancer (radiation or chemotherapy) within the past 1 year) Living outside study site or planning to move out of area in next 1 year or leave the area for >3 months during next year Exclusion criteria that apply only to those who received losartan or placebo of losartan Intolerance or allergy to angiotensin receptor blockers Known bilateral renal artery stenosis or liver cirrhosis Hypotension (systolic blood pressure <110 mmHg or diastolic blood pressure <60 mmHg) Serum potassium ≥5.4 mEq/L Use of lithium salts Estimated glomerular filtration rate <15 mL/min/1.73 m 2 Congestive heart failure with ejection fraction <40% Exclusion criteria that apply only to those who receive x-3 Intolerance or allergy to x-3, fish, shellfish, x-3 polyunsaturated fatty acids, fish oil (generic or specific, e.g., salmon, krill, cod liver oil), flax, or flaxseed oil Fatty fish intake >2 servings per week on average (salmon, trout, bluefish, mackerel, halibut, herring, tuna) History of paroxysmal or persistent atrial fibrillation To maintain blinding, those who were not eligible to receive any active treatment (x-3 or losartan) were excluded. Temporary exclusion criteria Myocardial infarction, coronary artery bypass graft, or valve replacement within past 6 months Pulmonary embolism or deep venous thrombosis within past 6 months Uncontrolled diabetes mellitus with recent weight loss, diabetic coma, or frequent insulin reactions Stroke, hip fracture, hip or knee replacement, or spinal surgery within past 4 months Physical therapy for gait, balance, or other lower extremity training within past 2 months Severe hypertension (e.g., systolic blood pressure >200 mmHg or diastolic blood pressure >110 mmHg) Serum of 25-OH Vitamin D level <20 ng/mL (dropped as a criterion during recruitment period) Hemoglobin <10 g/dL Participation in another intervention trial within 3 months; participation in an observational study may be permitted Current smoking within 6 months Acute infection (e.g., urinary, respiratory) or hospitalization within 1 month Exclusion criteria that apply only to those who received losartan or placebo of losartan Use of angiotensin-converting enzyme inhibitor of angiotensin receptor blocker within 2 months Use of aliskiren within 2 months in individuals with type 2 diabetes mellitus or renal impairment with estimated glomerular filtration rate <60
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Use of potassium-sparing diuretics, other medications with potassium-sparing properties (e.g., spironolactone, eplerenone), potassium supplements, and salt substitutes containing potassium within 1 week Transaminases more than twice upper limit of normal, to exclude participants with impaired liver function Exclusion criteria that apply only to those who received x-3 or placebo of w-3 Use of x-3 polyunsaturated fatty acids, fish oil (generic or specific, e.g., salmon, krill, cod liver oil), flax or flaxseed oil within 2 months To maintain blinding, those who were not eligible to receive any active treatment (x-3 or losartan) were excluded
Biological samples were collected, prepared, handle, and stored following standard operating procedures that complied with the NIH Office of Extramural Research requirements and guidelines.
Secondary outcomes included physical performance, frailty, muscle strength, and inflammatory biomarkers to characterize the effect of the interventions.
Physical performance was measured using the Short Physical Performance Battery (SPPB), which is based on a timed 4-m walk and balance and chair stand tests. 18 Frailty was characterized using the Fried criteria (selfreported exhaustion, unintentional weight loss, low energy expenditure, slow gait speed, weak grip strength). 19 Muscle strength was measured using maximal tests of isometric grip strength and isokinetic leg extension and flexion strength. 17, 20 Maximal grip strength force was measured two times in kilograms in both hands using a handheld dynamometer (Jamar, Lafayette Instruments, Lafayette, IN). Maximal isokinetic leg extension and flexion torque was measured in both legs with two trials of five repetitions at 60°and 180°per second on an isokinetic dynamometer (Biodex Inc., Shirley, NY).
Additional inflammatory markers were measured in exploratory analyses. These included novel (soluble CD163 (sCD163), soluble IL-2 receptor alpha (sIL2R-a), soluble tumor necrosis factor alpha receptor 1 (sTNFaR1)) and traditional (C-reactive protein) inflammatory markers. sCD163 is a biomarker of monocyte activation that is related to cardiovascular disease risk and mortality in elderly adults.
21 sIL2R-a is a marker of T-cell activation and can result in accelerated loss of thymic function and adaptive immunity with chronic overexpression. 22 sTNFaR1 has emerged as a superior surrogate marker of TNF-a, yielding data with considerably less analytical variability 23 .-sTNF alpha symbol it is liberated from multiple cell types through the action of TNF-a and is therefore a biomarker of its activity.
Sample size
The target sample size (N = 300) was determined based on marginal comparisons (135 and 165 per group) between each active intervention and placebo using a onesided hypothesis test at the 10% level. The goal was not to provide definitive evidence but to exclude small effects that would have lower clinical value. For IL-6, there was 91% power to detect a difference if the difference (on the log scale) was at least 0.1625 (or a 15% difference). There was 66% power for a 10% difference and 99% power for a 20% difference. For 400-m walk speed, there was greater than 99% power to detect more than 0.095 m/s (a substantial meaningful change) and 86% power for a difference of more than 0.038 m/s (a small meaningful change) in walking speed. Lastly, there was 90% power to detect a difference of at least 0.99 SPPB units.
Treatment Interventions and Randomization
Interventions consisted of losartan, x-3, and their combination in a double-blind, placebo-controlled randomized trial. x-3 fish oil and placebo (corn oil) were obtained from Epax (Aalesund, Norway) and had identical shape, color, taste, and weight. Purity and composition of x-3 was monitored using carbon-13 nuclear magnetic resonance spectroscopy. Losartan and placebo were obtained from Almac Group (Souderton, PA). Three groups of potential participants were evaluated for the ENRGISE Pilot Study. The first group consisted of potential participants who were not currently taking x-3 fatty acids, fish oil (generic or specific, e.g., salmon, krill, cod liver oil), flax, or flaxseed oil or were not consuming more than two servings of fatty fish per week (e.g., salmon, trout, bluefish) but were taking an ARB or ACEI. This group was randomized to placebo x-3 or active x-3. The second group consisted of potential participants who were not using an ACEI or an ARB but were taking x-3. This group was randomized to placebo losartan or active losartan. The third group consisted of people not using x-3 or consuming other sources of polyunsaturated fatty acids as described above, an ARB, or an ACEI. This group was randomized to placebo losartan/placebo x-3, placebo losartan/active x-3, active losartan/placebo x-3, or active losartan/active x-3. Table 2 shows randomization strata and number of participants in each group according to baseline losartan and x-3 use. A permuted block algorithm (with random block lengths) was used for randomization, which was concealed using a secure web-based data management system.
Dose, Titration Plan, and Adherence
Participants randomized to the x-3 arm began with 1.4 g/d (administered in 0.7-g gel caps) until the 6-month followup visit. Each 0.7 g of fish oil contained 400 mg of eicosapentaenoic acid and 200 mg of docosahexaenoic acid. Losartan was obtained in 25-and 50-mg capsules. Losartan and placebo were each encapsulated so that they were identical in shape, color, taste, and weight. Participants randomized to losartan began with 25 mg/d. If this dose was tolerated, based on the safety assessment that included reported symptoms and blood pressure measurement 1 to 2 weeks after the start of losartan, the dose of losartan was increased to 50 mg/d. If there were no safety concerns, the dose of 50 mg/d was continued until the 6-month visit. At 6-month follow-up, the dose of x-3 was increased to 2.8 g/d, and losartan was increased to 100 mg/d if the average of IL-6 measured at the 3-and 6-month visits did not decrease by at least 40% from baseline (average of screening visits 1 and 2). The 40% threshold was selected based on findings of previous trials, which showed IL-6 reductions of greater than 50%. 24, 25 Adherence to the interventions was monitored using pill counts at scheduled clinic visits and participant report. For the latter, participants were asked how many times they were not able to take the study drug and to rate their ability to take it during the past month (e.g., excellent, fair, poor).
Safety Measures
Safety visits consisted of a follow-up visit after initiating or increasing the study drug to assess the safety of the medication increase. They were also scheduled to follow participants who required a dose reduction because of symptoms or abnormal findings or at the medical safety officer's discretion. The safety visits were conducted within 1 to 2 weeks of a change in study medication and consisted of medical history follow-up, medication inventory, measurement of vital signs (blood pressure, pulse, weight, temperature), laboratory tests relevant to the medication change, and assessment of medication adherence. No drugs were dispensed at safety visits. Drug dispensing occurred only once laboratory results were obtained.
Measurements to evaluate safety consisted of blood pressure, hemoglobin, serum glucose, renal function (estimated glomerular filtration rate), low-density lipoprotein cholesterol, and potassium at baseline and 3-, 6-, and 9-month follow-up. These measurements were also made 1 to 2 weeks after randomization for participants randomized to losartan/placebo. If serum potassium rose above 5.0 mEq/L or estimated glomerular filtration rate dropped by more than 20% from baseline, losartan treatment was discontinued. If blood pressure dropped to less than 90/ 50 mmHg (hypotension) or a participant experienced new symptoms of hypotension such as dizziness or presyncope, losartan dose was reduced or losartan was discontinued. For x-3, if there was a new onset of atrial fibrillation, hemoglobin decreased by more than 20%, or fasting glucose or low-density lipoprotein cholesterol significantly increased from a previous visit, x-3 was discontinued. Laboratory tests and blood pressure measurement were repeated whenever a dosage adjustment was made in response to an abnormal laboratory test result or blood pressure value. Blood testing was also repeated at the investigator or medical safety officer's discretion.
DISCUSSION
The ENRGISE Pilot Study was designed to test whether antiinflammatory interventions would improve or preserve walking ability in older adults with mobility impairments. The investigators selected interventions that are widely available, safe, tolerable, acceptable, and affordable for vulnerable older persons. In addition, to maximize the antiinflammatory effect and potential effect on mobility, the investigators tested individual and combination interventions.
Choice of Potential Candidate Drugs
Potential candidate interventions were assessed using the following criteria: excellent safety record, ability to reduce high IL-6 levels, demonstrated benefits in improving physical performance, considered innovative for affecting mobility outcomes, were tested in trials with complimentary biological mechanisms and broadly available at low cost. A number of candidate interventions were excluded from consideration based on the a priori criteria listed in Table 3 . Under the first criterion, anti-TNF-a agents (etanercept, infliximab, adalimumab), 26 anti-IL-6 agents (siltuximab), 27 anti-IL1-(canakinumab-no long-term safety data available), 28 and thiazolidinediones (rosiglitazone, pioglitazone) 29 were excluded based on risk of infection, liver toxicity, fluid overload, cardiovascular disease, fracture, or possible cancer. Chloroquine and statins were excluded out of concern about myotoxicity and lack of effect on walking speed for statins (Criteria 1 and 5). 30 Corticosteroids, aspirin, nonsteroidal antiinflammatory drugs (NSAIDs), and cyclooxygenase-2 (cox-2) inhibitors were excluded because of risk of bleeding, 31 gastrointestinal toxicity, and cardiovascular events for NSAIDs and cox-2 inhibitors. 32 Colchicine was excluded because of risk of myotoxicity 33 and neuropathy (Criteria 1 and 5). 34 Low-dose methotrexate is potentially safe and effective in lowering IL-6 but was not acceptable because it has the stigma of being a "dangerous" anticancer drug. Criterion 2 excluded promising interventions, such as metformin, ghrelin, lactoferrin, oxytocin, salsalate, creatine, curcuma, probiotics, and resveratrol because of lack of clinical trial evidence for reducing IL-6. Metformin, although potentially promising, slightly reduced CRP in the Diabetes Prevention Project (-12%), 35 in part because of its modest weight-reducing effect, although other trials have shown no effect on IL-6 36 or CRP. 37 Despite the numerous potential antiinflammatory interventions cited in the literature, most were deemed to have limited public health effect for prevention because of safety and high cost.
Only two potential interventions met the a priori inclusion criteria. First, ACEIs and ARBs have shown excellent safety in large hypertension and heart failure trials in older persons. Of ACEIs, perindopril 38 and enalapril 39 have been found to reduce IL-6. Perindopril has been shown to prevent declines in physical function and walking speed in older persons 40 and to reduce CRP 41 . Most ARBs (except Did not receive placebo omega 3 fish oil (x-3) because the use of the corresponding drugs was permitted at baseline. ACEI=angiotensin-converting enzyme inhibitor; ARB=angiotensin receptor blocker.
azilsartan) reduce high IL-6 and were prioritized over ACEIs because they exhibit greater tolerability. 42 A second intervention meeting a priori inclusion criteria was x-3 43 and lipoic acid 44 , which have been found to reduce IL-6 and CRP 43 in randomized clinical trials. In older women, x-3 improved walking speed 45 and muscle strength when supplemented with exercise. 46 Losartan 47 and x-3 48 also have supplementary effects on vasculature, coagulation, metabolism, and skeletal muscle, all of which may benefit mobility ( Figure 1 ). The combination of these interventions may reveal an additive effect on walking speed. The final decision was to prioritize losartan and x-3 (and their combination) because they have been show to reduce IL-6 by more than 40% in randomized clinical trials and because of their excellent safety records, high tolerability, long history of trials, shared complementary biological mechanism and low cost. (Losartan is 1/50 the cost of other ARBs.) 24, 25 
Challenges and Limitations
Pilot studies, by their nature, have inherent challenges and limitations. First, although there was ample justification for choosing IL-6 as a marker of chronic low-grade inflammation, it may not have the most-robust association with the physical function outcomes. To evaluate this possibility, ENRGISE investigators assessed other markers of inflammation to compare sensitivity to change and association with the physical function outcomes of interest. The major challenges of the ENRGISE Pilot Study were identifying participants who met the IL-6 criteria while also having mobility impairments and yet were medically safe enough to participate. The joint prevalence of these criteria was largely unknown. In addition, the MMD outcome required a large sample size to identify group differences. 49 If the MMD outcome proved to be too infrequent for a larger study, the proportion of participants who changed their walking speed by a small yet clinically meaningful amount was an alternative primary outcome for the main trial. Another important limitation of the design was that lowering of inflammation and improved or preserved walking speed may not be directly linked to each other. The interventions tested have a myriad of biological effects that could positively affect mobility (e.g., improved blood flow with ARBs, brain function, lipid profiles), and these would be challenging to mechanistically separate from their effects on inflammation in the current design. Illustration of selected mechanisms that may lead to progressive mobility disability that may be amenable to intervention using antiinflammatory inventions being proposed by the ENabling Reduction of low-Grade Inflammation in SEniors Pilot Study. The three main sources of inflammation in elderly adults (genetic and epigenetic, exogenous, endogenous factors) combine to cause molecular and biochemical changes that in turn lead to physiological consequences and ultimately to mobility limitation and mortality.
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